Diederichs Solvig, Gabler Jessica, Autenrieth Jennifer, Kynast Katharina L, Merle Christian, Walles Heike, Utikal Jochen, Richter Wiltrud
1 Research Center for Experimental Orthopedics, Orthopedic University Hospital Heidelberg , Heidelberg, Germany .
2 Clinic for Orthopedics and Trauma Surgery, Orthopedic University Hospital Heidelberg , Heidelberg, Germany .
Stem Cells Dev. 2016 Apr 15;25(8):598-609. doi: 10.1089/scd.2015.0312. Epub 2016 Mar 23.
Induced pluripotent stem cells (iPSCs) are an attractive cell source for cartilage regeneration, but current in vitro chondrogenic differentiation protocols yield insufficient results. In search for shortcomings of iPSC chondrogenesis, this study investigated whether SOX9 protein was adequately regulated during multiphase chondrogenic differentiation of two human iPSC lines in a comparable manner like during mesenchymal stromal cell (MSC) chondrogenesis. Upon generation of intermediate mesenchymal progenitor cells (iMPCs), SOX9 was induced and reached variable protein levels compared to MSCs. Along with an altered condensation behavior, iMPC cartilage formation was less robust compared to MSCs and better in the iMPC line with higher SOX9 protein levels. Despite efficient Smad-2/3 phosphorylation, TGF-β-driven chondrogenic stimulation downregulated SOX9 protein in iMPCs rather than increasing levels like in MSCs. Chondrogenesis was further improved by cotreatment with TGF-β + BMP-4, which appeared to shorten the duration of the SOX9 protein decline. However, this was insufficient to overcome heterogenic outcome and came at the expense of undesired hypertrophy. In iMPCs, but not MSCs, high levels of the SOX9-antagonizing hsa-miR-145 correlated with low SOX9 protein quantity. Thus, considerable iMPC heterogeneity with variable SOX9 protein levels, an altered condensation pattern, and low early SOX9 inducibility appeared as critical shortcomings of iPSC chondrogenesis. We suggest consistent quality of intermediate cell populations with high SOX9 protein induction as important indicators to obtain robust cartilage formation from iPSCs. The impact of this study is the identification of a SOX9 protein regulation opposite to MSC chondrogenesis that will now enable a selective adaptation of the currently limited protocols to the specific needs of iPSCs.
诱导多能干细胞(iPSC)是软骨再生的一种有吸引力的细胞来源,但目前的体外软骨生成分化方案效果不佳。为了寻找iPSC软骨生成的缺点,本研究调查了在两个人类iPSC系的多阶段软骨生成分化过程中,SOX9蛋白是否像间充质基质细胞(MSC)软骨生成过程中那样以可比的方式得到充分调节。在产生中间间充质祖细胞(iMPC)后,SOX9被诱导,与MSC相比达到了不同的蛋白水平。随着凝聚行为的改变,iMPC软骨形成与MSC相比不太稳健,在SOX9蛋白水平较高的iMPC系中更好。尽管Smad-2/3磷酸化有效,但TGF-β驱动的软骨生成刺激下调了iMPC中的SOX9蛋白,而不是像在MSC中那样增加其水平。用TGF-β + BMP-4联合处理进一步改善了软骨生成,这似乎缩短了SOX9蛋白下降的持续时间。然而,这不足以克服异质性结果,并且是以不期望的肥大作为代价。在iMPC中,而不是在MSC中,高水平的SOX9拮抗物hsa-miR-145与低SOX9蛋白量相关。因此,具有可变SOX9蛋白水平的相当大的iMPC异质性、改变的凝聚模式和低早期SOX9诱导性似乎是iPSC软骨生成的关键缺点。我们建议将具有高SOX9蛋白诱导的中间细胞群体的一致质量作为从iPSC获得稳健软骨形成的重要指标。本研究的影响是确定了与MSC软骨生成相反的SOX9蛋白调节,这将使目前有限的方案能够根据iPSC的特定需求进行选择性调整。